[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,70,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642375","gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer-100642375",false,"NCT07661017","GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer","Inclusion\n\nSurvivors of GI cancer are eligible if they are:\n\n* ≥18 years old\n* reside in or have received cancer care in Minnesota\n* own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).\n* are English-speaking\n* have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)\n* At least 2 months post-cancer treatment\n\nInclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:\n\n* Have interacted with at least 1 cancer patient or survivor in the past month.\n* Have experience working with electronic health records (EHR).\n\nExclusion\n\n* Currently pregnant (Patient Study ONLY)\n* Pregnancy status may be self-reported by the participant.\n* Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.\n* Active cancer or receiving treatment for another cancer.\n* Currently taking or has taken antibiotics in the last 3 months.\n* Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and\u002For celiac disease.\n* Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.\n\nOncology specialists' exclusion criteria include:\n\n* Unable to participate in an interview",true,"ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","There are two components to the study: a patient and a clinician study. The clinician study will include one-hour semi-structured interviews with oncology specialists to identify facilitators and barriers to integrating digital diet interventions into the clinical workflow, and to understand their needs and preferences for digital diet interventions. The patient study aims to investigate initial feasibility, efficacy and acceptability of the GutCheck app and intervention. It will last 9 weeks and involves 2 study visits and 2 active phases with a transition week and optional transition visit between phases. During active phases, participants will be asked to use the GutCheck app every day. Prior to the first active phase, participants will go through informed consent and app training. The first active phase will last two weeks and will focus on tracking participants' diet, gastrointestinal (GI) symptoms, and stress. The data collected during the first active phase will be used to identify any potential trigger foods that may contribute to GI symptoms, but only if the participant reports experiencing GI symptoms. Between active phases, participants will have one Transition Week, where results from the first phase are given to the participants with the option to attend a Transition Week Visit. The second active phase will last four weeks and will involve the message intervention. A single-blind, micro-randomized trial design will be used to repeatedly randomize participants to different intervention combinations, determining both the timing and frequency of intervention message delivery throughout the day. Lastly, there will be an exit visit and interview within a week from the intervention to collect post-intervention measures and ask about the participant's experience with the GutCheck app.",[26,27,28,29,30,31,32],"Gastrointestinal","Mobile Health","Gastrointestinal Symptoms","Gut Health","Gastrointestinal Cancer","Survivorship","GI Cancer","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":20},"2026-12",{"date":41,"type":20},"2030-06",{"name":43,"class":44},"Masonic Cancer Center, University of Minnesota","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100620285","terraflora-daily-care-and-gastrointestinal-health-100620285","NCT07355634","Terraflora Daily Care and Gastrointestinal Health","A Randomized, Placebo-Controlled Trial Evaluating the Impact of a Synbiotic Dietary Supplement on Markers of Gastrointestinal Health","Inclusion Criteria:\n\n1. Adult males or females age ≥ 25 years\n2. Ability to read and speak English\n3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)\n\nExclusion Criteria:\n\n1. Daily use within the past month of any probiotic or prebiotic supplement\n2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis\n3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications\n4. Current daily tobacco smoker\n5. Known allergies to any substance in the study products\n6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol\n8. Current participation in another clinical trial\n9. Participants unable to provide consent","25 Years",{"count":54,"type":20},40,[23],"A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.",[26],"RECRUITING","2026-05-05",{"date":61,"type":37},"2026-05-11",{"date":63,"type":37},"2026-01-12",{"date":65,"type":20},"2026-09",{"name":67,"class":68},"OvationLab","NETWORK",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":69},"100620358","neonatal-enterovirus-infections-in-italy-virological-characterization-genomic-and-clinical-epidemiological-insights-on-echovirus-11-100620358","NCT07356583","Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on Echovirus 11","Entero-Neo","Inclusion Criteria:\n\nSamples from consecutive neonates admitted to neonatal intensive care unit.\n\nExclusion Criteria:\n\nInsufficient residual samples (volume less than 1 mL of nasal swab) will be excluded from the study","1 Day","28 Days",{"count":80,"type":20},1600,"OBSERVATIONAL","The Enterovirus genus, belonging to the Picornaviridae family, consists of positively polarized single-stranded RNA viruses classified into the species Enterovirus (EV, comprising Coxsackievirus, Echovirus and Poliovirus) A-J and Rhinovirus (RV) A-C, of which more than 200 different genotypes have been described. Enteroviruses have a global spread and are a common cause of febrile, gastroenteric and exanthematous diseases, usually self-limiting, which are widespread in infants and pediatric populations. However, they can occasionally cause serious diseases, including meningoencephalitis, myelitis, paralysis, myocarditis, sepsis, severe respiratory syndromes, and acute hepatitis. They can be transmitted by respiratory route, with most cases in temperate regions occurring during summer and early autumn. Enteroviruses are characterized by a rapid evolution determined by the high mutation rate (due to the presence of an RNA-dependent RNA-polymerase that lacks proofreading activity) and the high probability of undergoing recombination events. The latter, in particular inter-typical recombination, plays a crucial role in the evolutionary process of Enteroviruses and has been recognized as a major cause of the emergence of strains with higher pathogenicity and\u002For epidemic potential, although the associated genetic determinants are not known to date. Between July 2022 and April 2023, nine cases of neonatal Echovirus 11 (E-11) infection with severe liver failure and neurological and myocardial involvement were reported in France; seven of these cases resulted in fatal outcomes. Following these reports, the World Health Organization (WHO) issued an alert that quickly led to the identification of further cases in Italy, Spain, Croatia and the United Kingdom. As EV infections are not subject to systematic surveillance, there is a lack of data on the actual burden of disease associated with these infections. Thus, EV infections are underestimated and, even more so, data on their typing are scarce - if not absent -, which involve second-level analyses that are generally not carried out routinely in clinical microbiological diagnostic laboratories, are rarely available and are not systematically collected, not even at European level. A condition that therefore makes it impossible to estimate either the impact of EV infections in general, and of E-11 in particular, or the risk factors related to the most serious cases and the most significant transmission routes. Moreover, the characteristics of the immunological and inflammatory response to infection remain to be defined. These elements would allow, if available, the formulation of a specific case definition to ensure rapid laboratory confirmation and recognition of the disease.To strengthen knowledge of the spread and impact of enterovirus infections in newborns, with a focus on E-11, by carrying out the following activities, within the scope of the project's proposed objectives: design and pilot implementation (proof of concept) of epidemiological and genomic surveillance systems with potential national application; molecular characterization and evaluation of viral pathogenic features; search for possible immunological markers and host risk factors associated with severe EV disease, including E-11.\n\nSpecific objectives\n\n1. To implement and validate a protocol for screening activities in neonatal units and neonatal intensive care units aimed at checking for the presence of infections caused by EV and identifying severe forms of infection, with particular attention to E-11.\n2. Characterize EV strains, identified within the activities carried out by specific objectives 1, using next-generation sequencing (NGS) approaches to obtain the whole genome sequence and identify possible recombinant forms. Carry out phylogenetic analysis of the obtained sequences compared with those deposited in the main international databases, to define genomes that can be traced back to variant strains or with specific mutations in the genome.",[84,85,86,26,87],"Enterovirus","Clinical Syndrome","Respiratory Complications","Sepsis",[89],"Enterovirus, E-11, NGS","2026-03-26",{"date":92,"type":37},"2026-03-27",{"date":94,"type":37},"2026-02-01",{"date":96,"type":20},"2027-02-01",{"name":98,"class":44},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100608145","early-phase-1-vitamin-c-with-steroids-for-gastrointestinal-gvhd-100608145","NCT07197749","Vitamin C With Steroids for Gastrointestinal GVHD","Administration of Vitamin C (Ascorbic Acid) With Steroids for First Line Therapy of Gastrointestinal GVHD","Inclusion Criteria:\n\n1. Patients 5 years of age or older at time of enrollment.\n2. Patients experiencing their initial presentation of stage 2 or greater acute LGI GVHD (with or without other organ involvement) or stage 1 LGI + skin aGVHD requiring systemic therapy after allogeneic transplant for any malignant or non-malignant indication using any graft\u002Fdonor source or conditioning intensity.\n3. KPS ≥70%\n4. Patients should not have received systemic immune suppressive therapy for treatment of active GVHD except for a maximum of 72 hours of steroid therapy (with or without ruxolitinib) prior to enrollment. Topical skin and GI corticosteroids (such as budesonide and oral beclomethasone diproprionate) are allowed.\n5. Informed Consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nExclusion Criteria:\n\n1. Relapsed, progressing or persistent malignancy or evidence of minimal residual disease (MRD) requiring withdrawal of systemic immune suppression.\n2. Patients with acute GVHD developing after administration of a donor lymphocyte infusion (DLI) for relapse\u002Fprogression of disease.\n3. Patients with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms\n4. Known or suspected hypersensitivity to vitamin C.\n5. De novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment.\n6. Patients receiving other drugs for the treatment of GVHD except as noted above. GVHD prophylaxis agents (e.g., calcineurin inhibitors) may be continued at local Investigator's discretion.\n7. Patients on renal replacement therapy.\n8. Patients requiring continuous supplemental oxygen \\> 2L\u002Fmin to maintain peripheral O2 saturation \\[SpO2\\] \\> 90%.\n9. Patients with active hepatic sinusoidal obstructive syndrome (SOS) and\u002For clinical evidence of impaired hepatic function (ascites or encephalopathy related to liver disease.\n10. Patients receiving systemic corticosteroids (CS) for any indication within 7 days before enrollment, except the following:\n\n    1. Corticosteroids administered as premedication for supportive care (such as before transfusion of blood products or before intravenous medications to prevent infusion reactions, fever, etc.).\n    2. If steroid therapy has been administered for treatment of a non-GVHD related condition and tapered to \\\u003C 0.6 mg\u002Fkg\u002Fday prednisone (0.5 mg\u002Fkg\u002Fday methylprednisolone) for 7 or more days prior to enrollment.\n11. History of G6PD deficiency, sickle cell disease or hemochromatosis.\n12. History of oxalate kidney stones.\n13. Patients unlikely to be adherent to study specific assessments at the transplant center.","5 Years",{"count":108,"type":20},35,[110],"EARLY_PHASE1","After a transplant from another donor, one risk is graft versus host disease (GVHD) that happens because of differences between the donated cells (graft) and the patient's body cells (host). The new cells from the donor might see the body's cells as different and attack them. GVHD can be very serious and cause death. The standard first treatment for GVHD is corticosteroids but not all patients respond and in cases where they don't, they need to go onto other treatments that may or may not be effective. In addition, when GHVD involves the gut it can damage the cells of the gastrointestinal track causing long term problems such as abdominal pain and bowel disturbance. In laboratory studies giving a vitamin C has been able to protect the gastrointestinal cells and help them recover. In this trial the investigators would like to see if vitamin C can do the same thing when given with steroids in patients with GVHD.\n\nThe standard first treatment for acute GVHD is corticosteroids but not all patients respond and in cases where they don't, they need to go onto other treatments that may or may not be effective. In addition, when GHVD involves the gut it can damage the cells of the gastrointestinal track causing long term problems such as abdominal pain and bowel disturbance. In the laboratory vitamin C has been able to protect gut stem cells and help them recover and the investigators would like to learn if this happens in people too.\n\nVitamin C is a readily available supplement. Vitamin C has NOT been approved by the FDA for the treatment of acute GVHD.",[113,26],"Graft-versus-host-disease (GVHD)",[115,116,117,26],"Graft-Versus-Host-Disease","GVHD","Vitamin C","2026-03-03",{"date":120,"type":37},"2026-03-04",{"date":122,"type":20},"2026-06",{"date":124,"type":20},"2029-10",{"name":126,"class":44},"Baylor College of Medicine"]